Meenakshi Bewtra1, Colleen M Brensinger, Vesselin T Tomov, Tram B Hoang, Carly E Sokach, Corey A Siegel, James D Lewis. 1. *Department of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania; †Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania; and ‡Inflammatory Bowel Disease Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Abstract
BACKGROUND: There is a need for simple, noninvasive patient-driven disease assessment instruments in ulcerative colitis (UC). We sought to further assess and refine the previous described 6-point Mayo score. METHODS: A cross-sectional study of 282 UC patients was conducted assessing the correlation of the 2 patient-reported Mayo score components (6-point Mayo score) with the simple clinical colitis activity index (SCCAI) and a single Likert scale of patient-reported disease activity. Spearman's correlation, sensitivity, specificity, and area under the receiver operating curves (AUC) were calculated. A separate validation study in 59 UC patients was also conducted. RESULTS: Participants predominantly had long-standing disease (83%) and were in self-reported remission (63%). The 6-point Mayo score correlated well with the SCCAI (rho = 0.71; P < 0.0001) and patient-reported disease activity (rho = 0.65; P < 0.0001). Using a cutpoint of 1.5, the 6-point Mayo score had 83% sensitivity and 72% specificity for patient-defined remission, and 89% sensitivity and 67% specificity for SCCAI-defined remission (score, <2.5). The 6-point Mayo score and SCCAI had similar accuracy of predicting patient-defined remission (AUC = 0.84 and 0.87, respectively). Addition of the SCCAI general well-being question to the 6-point Mayo improved the predictive ability for patient-defined remission; and a new weighted score had an AUC of 0.89 in the development cohort and 0.93 in the validation cohort. The optimal cutpoint was 1.6. CONCLUSIONS: The patient-reported UC severity index that includes stool frequency, bleeding, and general well-being accurately measures clinical disease activity without requiring direct physician contact.
BACKGROUND: There is a need for simple, noninvasive patient-driven disease assessment instruments in ulcerative colitis (UC). We sought to further assess and refine the previous described 6-point Mayo score. METHODS: A cross-sectional study of 282 UC patients was conducted assessing the correlation of the 2 patient-reported Mayo score components (6-point Mayo score) with the simple clinical colitis activity index (SCCAI) and a single Likert scale of patient-reported disease activity. Spearman's correlation, sensitivity, specificity, and area under the receiver operating curves (AUC) were calculated. A separate validation study in 59 UC patients was also conducted. RESULTS:Participants predominantly had long-standing disease (83%) and were in self-reported remission (63%). The 6-point Mayo score correlated well with the SCCAI (rho = 0.71; P < 0.0001) and patient-reported disease activity (rho = 0.65; P < 0.0001). Using a cutpoint of 1.5, the 6-point Mayo score had 83% sensitivity and 72% specificity for patient-defined remission, and 89% sensitivity and 67% specificity for SCCAI-defined remission (score, <2.5). The 6-point Mayo score and SCCAI had similar accuracy of predicting patient-defined remission (AUC = 0.84 and 0.87, respectively). Addition of the SCCAI general well-being question to the 6-point Mayo improved the predictive ability for patient-defined remission; and a new weighted score had an AUC of 0.89 in the development cohort and 0.93 in the validation cohort. The optimal cutpoint was 1.6. CONCLUSIONS: The patient-reported UC severity index that includes stool frequency, bleeding, and general well-being accurately measures clinical disease activity without requiring direct physician contact.
Authors: Geert D'Haens; William J Sandborn; Brian G Feagan; Karel Geboes; Stephen B Hanauer; E Jan Irvine; Marc Lémann; Philippe Marteau; Paul Rutgeerts; Jurgen Schölmerich; Lloyd R Sutherland Journal: Gastroenterology Date: 2006-12-20 Impact factor: 22.682
Authors: James D Lewis; Shaokun Chuai; Lisa Nessel; Gary R Lichtenstein; Faten N Aberra; Jonas H Ellenberg Journal: Inflamm Bowel Dis Date: 2008-12 Impact factor: 5.325
Authors: Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes Journal: Gastroenterology Date: 2004-02 Impact factor: 22.682
Authors: M D Rutter; B P Saunders; K H Wilkinson; S Rumbles; G Schofield; M A Kamm; C B Williams; A B Price; I C Talbot; A Forbes Journal: Gut Date: 2004-12 Impact factor: 23.059
Authors: Maria Paula Henao; Meenakshi Bewtra; Mark T Osterman; Faten N Aberra; Frank I Scott; Gary R Lichtenstein; Jennifer Kraschnewski; James D Lewis Journal: Inflamm Bowel Dis Date: 2015-10 Impact factor: 5.325
Authors: Burcin Özdirik; Martin Maibier; Maria Scherf; Jule Marie Nicklaus; Josephine Frohme; Tobias Puengel; Dirk Meyer Zum Büschenfelde; Frank Tacke; Tobias Mueller; Michael Sigal Journal: J Clin Med Date: 2022-04-28 Impact factor: 4.964
Authors: Silvio Danese; Rupa Banerjee; Jr Fraser Cummings; Iris Dotan; Paulo G Kotze; Rupert Wing Loong Leong; Kristine Paridaens; Laurent Peyrin-Biroulet; Glyn Scott; Gert Van Assche; Jan Wehkamp; Jesús K Yamamoto-Furusho Journal: Intest Res Date: 2018-10-16
Authors: Alissa Walsh; Rena Cao; Darren Wong; Ramona Kantschuster; Lawrence Matini; Jean Wilson; Andrey Kormilitzin; Matthew South; Simon Travis; Sarah Bauermeister Journal: BMC Gastroenterol Date: 2021-03-22 Impact factor: 3.067
Authors: Emma M van Andel; Brechtje D M Koopmann; Femke Crouwel; Casper G Noomen; Nanne K H de Boer; Dirk P van Asseldonk; Lidwine B Mokkink Journal: J Crohns Colitis Date: 2020-09-16 Impact factor: 9.071